Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research
CAMBRIDGE, Mass., Feb. 20, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with the University of Alabama at Birmingham (UAB) to support their research in B cell development. Under the terms of the agreement, UAB,...
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the United States (US) Food and Drug Administration (FDA) has granted Fast Track...
Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New IndicationsKRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments + Double-Digit Percentage Royalties SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen, a leading biotechnology company specializing in exosome-based therapeutics, has announced a technology transfer and licensing agreement with BMI Korea for BxC-I17e, an innovative exosome-based injectable...
BluMaiden Biosciences Appoints New US-based Leadership to Accelerate Global Expansion
- Dr. Terence Kelly named interim CEO and Prof. Damian O'Connell named Chair of the Scientific Advisory Board, joins Board of Directors- Appointment of US-based CEO completes the recent build out of BluMaiden's executive team in preparation for commercialization, supported by COO Dr. Damien Keogh and CFO Kenneth Ling- BluMaiden's differentiated AI drug discovery approach bridges the gap with...
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg).- ASC30 oral once-daily tablet also demonstrated a 4.3% mean body weight reduction from baseline after 28-day treatment in MAD cohort 1 (weekly titrations of...
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment of Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biotech R&D, clinical and regulatory development, Dr. Lin will play a pivotal role in...
CKGSB and Johns Hopkins University Launch AI-Driven Healthcare Innovation Program
BEIJING, Feb. 19, 2025 /PRNewswire/ -- The Cheung Kong Graduate School of Business (CKGSB) and Johns Hopkins University's Carey Business School are proud to announce the launch of the AI-Driven Healthcare Innovation Program, a pioneering joint initiative designed to empower senior leaders, entrepreneurs, and innovators in the healthcare and technology sectors. This program, to be held at Johns Hopkins' Washington,...
Hong Kong to Host Landmark International Symposium on Genomic Medicine
HKGI Partners with Global Leaders to Chart a Course for Healthcare Transformation HONG KONG, Feb. 19, 2025 /PRNewswire/ -- Genomic medicine has been gaining global prominence for its vast potential to revolutionise healthcare services. In the case of rare conditions, genomic medicine has been particularly transformative, as approximately 80% of rare diseases are of genetic origin. Genomic medicine...
SingHealth and Philips sign MOU to advance digital-first healthcare to future-proof care delivery
New partnership set to accelerate digital healthcare transformation in Singapore, with a focus on co-designing and integrating Artificial Intelligence (AI) and predictive data management to improve patient care by 2028 Projects under this partnership aim to: o Streamline imaging data workflows by developing a standardized data architecture for better diagnostics...
AESOP Technology Unveils World’s First Machine Learning Model to Combat Wrong-Site Surgery
SAN FRANCISCO, Feb. 19, 2025 /PRNewswire/ -- Wrong-site surgery (WSS), a critical "Never Event," represents a failure that should never occur in healthcare. Yet, due to underreporting, the true prevalence of these incidents remains obscured, jeopardizing patient safety and healthcare management. AESOP Technology, a medical AI startup, has developed an innovative solution: the Association Outlier Pattern (AOP) machine learning...
